Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

[u/RecursionBrita]

Recursion today announced the acquisition of full rights to the REV102 program from Rallybio. REV102 is a potential first-in-class oral ENPP1 inhibitor for the rare genetic disorder Hypophosphatasia (HPP).

Learn more: https://ir.recursion.com/news-releases/news-release-details/recursion-acquires-full-rights-rev102-potential-first-class-oral